The Generic Medicines Industry Association (GMiA) has signed a Strategic Agreement with the Australian Government to support the ongoing supply of affordable generic and biosimilar medicines in Australia and deliver a five year period of certainty for the industry that provides them.

The Agreement recognises the essential role of  generic medicines and biosimilars in delivering affordable healthcare through the Pharmaceutical  Benefits Scheme (PBS). It also  recognises the  significant savings that continue  to be delivered by  generic medicines and  biosimilars, first by  providing competition and  then through price  disclosure.

“Every time a patient or healthcare professional    uses a generic medicine or a biosimilar it saves  money that can be used to pay for newer PBS  medicines. GMiA members have, and continue to,  deliver billions of dollars in PBS savings,” said Mark Crotty, GMiA  Chairman.

“GMiA and the Government have a common interest in the ongoing and reliable access to affordable generic medicines and biosimilars, a strong PBS that can meet the current and future needs of Australians, and having a sustainable generic medicines sector,” he said.

For more details, go to: http://www.gmia.com.au/strategic-agreement-recognises-the-important-role-of-generic-and-biosimilar-medicines-in-delivering-affordable-healthcare/